Opioid-Related Trends in Active Duty Service Members During the Coronavirus Disease 2019 Pandemic

Author:

Sorensen Ian S12,Susi Apryl12,Andreason Paul3,Hisle-Gorman Elizabeth1,Jannace Kalyn C124,Krishnamurthy Jayasree1,Chokshi Binny1,Dorr Madeline12,Wolfgang Aaron S56,Nylund Cade M1

Affiliation:

1. Department of Pediatrics, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA

2. Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland 20817, USA

3. Retired , Kensington, MD 20895, USA

4. Departments of Physical Medicine & Rehabilitation, Uniformed Services University of the Health Sciences, Center for Rehabilitation Sciences Research , Bethesda, MD 20814, USA

5. Department of Psychiatry, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA

6. Department of Psychiatry, Yale School of Medicine , New Haven, CT 06511, USA

Abstract

ABSTRACT Introduction The USA is experiencing an opioid epidemic. Active duty service members (ADSMs) are at risk for opioid use disorder (OUD). The Coronavirus disease 2019 (COVID-19) pandemic has disrupted health care and introduced additional stressors. Methods The Military Healthcare System Data Repository was used to evaluate changes in diagnosis of OUD, medications for OUD (MOUD), opioid overdose (OD), and opioid rescue medication. ADSMs ages 18-45 years enrolled in the Military Healthcare System between February 2019 and April 2022 were included. Joinpoint Trend Analysis Software calculated the average monthly percent change over the study period, whereas Poisson regression compared outcomes over three COVID-19 periods: Pre-lockdown (pre-COVID-19 period 0) (February 2019-February 2020), early pandemic until ADSM vaccination initiation (COVID-19 period 1 [CP1]) (March 2020-November 2020), and late pandemic post-vaccination initiation (COVID-19 period 2 [CP2]) (December 2020-April 2022). Results A total of 1.86 million eligible ADSMs received care over the study period. Diagnoses of OUD decreased 1.4% monthly, MOUD decreased 0.6% monthly, diagnoses of opioid OD did not change, and opioid rescue medication increased 8.5% monthly. Diagnoses of OUD decreased in both COVID-19 time periods: CP1 and CP2: Rate ratio (RR) = 0.74 (95% CI, 0.68-0.79) and RR = 0.72 (95% CI, 0.67-0.76), respectively. MOUD decreased in both CP1 and CP2: RR = 0.77 (95% CI, 0.68-0.88) and RR = 0.86 (95% CI, 0.78-0.96), respectively. Adjusted rates for diagnoses of opioid OD did not vary in either COVID-19 time period. Opioid rescue medication prescriptions increased in CP1 and CP2: RR = 1.09 (95% CI, 1.02-1.15) and RR = 6.02 (95% CI, 5.77-6.28), respectively. Conclusions Rates of OUD and MOUD decreased, whereas rates of opioid rescue medication increased during the study period. Opioid OD rates did not significantly change in this study. Changes in the DoD policy may be affecting rates with greater effect than COVID-19 pandemic effects.

Funder

Uniformed Services University of the Health Sciences

Publisher

Oxford University Press (OUP)

Subject

Public Health, Environmental and Occupational Health,General Medicine

Reference34 articles.

1. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health;Ahrnsbrak

2. DOSE Dashboard: Nonfatal overdose data;National Center for Injury Prevention and Control: Centers for Disease Control and Prevention

3. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017;Florence;Drug Alcohol Depend,2021

4. Opioid use disorder;Dydyk,2022

5. Risk factors for opioid-use disorder and overdose;Webster;Anesth Analg,2017

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3